e-learning
resources
ERJ
2018
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
First histopathological evidence of irreversible pulmonary vascular disease in dasatinib-induced pulmonary arterial hypertension
Cécile Daccord, Igor Letovanec, Patrick Yerly, Jonathan Bloch, Adam Ogna, Laurent P. Nicod, John-David Aubert
Source:
Eur Respir J, 51 (3) 1701694; 10.1183/13993003.01694-2017
Journal Issue:
March
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Cécile Daccord, Igor Letovanec, Patrick Yerly, Jonathan Bloch, Adam Ogna, Laurent P. Nicod, John-David Aubert. First histopathological evidence of irreversible pulmonary vascular disease in dasatinib-induced pulmonary arterial hypertension. Eur Respir J, 51 (3) 1701694; 10.1183/13993003.01694-2017
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion on acute decompensated pulmonary hypertension
The definition of pulmonary hypertension: history, practical implications and current controversies
ERS statement on chronic thromboembolic pulmonary hypertension
Related content which might interest you:
Pulmonary hypertension in sickle cell disease
Source: Annual Congress 2007 - ACCP1 - Pulmonary hypertension in sickle cell disease
Year: 2007
Single arterial occlusion to locate resistance in patients with pulmonary hypertension
Source: Eur Respir J 2003; 21: 31-36
Year: 2003
The vascular bed in COPD: pulmonary hypertension and pulmonary vascular alterations
Source: Eur Respir Rev 2014; 23: 350-355
Year: 2014
Microvascular disease in chronic thromboembolic pulmonary hypertension: a role for pulmonary veins and systemic vasculature
Source: Eur Respir J 2014; 44: 1275-1288
Year: 2014
Beyond arterial remodelling: pulmonary venous and cardiac involvement in patients with systemic sclerosis-associated pulmonary arterial hypertension
Source: Eur Respir J 2010; 35: 6-8
Year: 2010
Tadalafil in idiopathic or heritable pulmonary arterial hypertension compared to pulmonary arterial hypertension associated with connective tissue disease
Source: Annual Congress 2011 - Treatment of human pulmonary hypertension
Year: 2011
Updates in pulmonary hypertension and other pulmonary vascular diseases
Source: Breathe, 15 (3) 241; 10.1183/20734735.0187-2019
Year: 2019
Pulmonary vascular distensibility in pulmonary hypertension due to left heart disease
Source: International Congress 2018 – Pulmonary hypertension: right ventricle function, haemodynamics and exercise
Year: 2018
Treatment of pulmonary hypertension in chronic obstructive pulmonary disease
Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-48-0, page=313
Year: 2006
The imPAHct of diagnosis delay in pulmonary arterial hypertension
Source: Annual Congress 2012 - Pulmonary circulation: clinical aspects of PAH, PTE and CTEPH
Year: 2012
Pulmonary hypertension in chronic obstructive pulmonary disease
Source: Eur Respir J 2003; 21: 892-905
Year: 2003
Pulmonary function in patients with idiopathic pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
Source: Annual Congress 2010 - Pulmonary circulation I
Year: 2010
Pulmonary hypertension in children
Source: Eur Respir Mon 2012; 57: 94-107
Year: 2012
MnTBAP reduces pulmonary vascular remodeling in experimental pulmonary arterial hypertension
Source: International Congress 2019 – Pulmonary hypertension: novelties from the bench
Year: 2019
Sitaxentan-induced hepatic failure in two patients with pulmonary arterial hypertension
Source: Eur Respir J 2009; 34: 770
Year: 2009
Long-term efficacy of bosentan in treatment of pulmonary arterial hypertension in children
Source: Eur Respir J 2011; 37: 70-77
Year: 2011
Impact on survival of pulmonary function abnormalities in pulmonary arterial hypertension
Source: Annual Congress 2009 - Pulmonary hypertension
Year: 2009
The transpulmonary pressure gradient for the diagnosis of pulmonary vascular disease
Source: Eur Respir J 2013; 41: 217-223
Year: 2013
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept